Price
No data yet.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $53.74M | $29.82M | $2.42 |
| 2024 | $0.00 | $-47.73M | $-5.12 |
| 2023 | $-6.65M | $-53.74M | $-4.51 |
| 2022 | $6.65M | $-42.81M | $-3.59 |
| 2021 | $0.00 | $-37.56M | $-3.15 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.34 per share
Typical surprise +26.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.44 vs $-0.46beat
- Tue, May 5$-0.54 vs $-0.68beat
- Tue, Mar 10$3.65 vs $-0.85beat
- Thu, Nov 13$-0.60 vs $-1.39beat
- Wed, Aug 6$-0.78 vs $-1.14beat
- Thu, May 8$-0.90 vs $-1.23beat
Estimates and results for QTTB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QTTB officers and directors.
- Bought
- $30.0m
- Sold
- $217k
4 trades
8 trades
- Xu Diyongbought
- Xu Diyongbought
- Orbimed Advisors Llcbought
- Orbimed Advisors Llcbought
- Kalowski Leesold
- Morrison Jodie Popesold
- Violette Shelia M.sold
- Morrison Jodie Popesold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.56
- Implied price
- $64.12
- Return from $15.96
- 32.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.88 — today's price is already 49.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 10.5% | 15.5% | 19.8% | 23.6% | 26.9% |
| 3.0% | 16.1% | 21.4% | 25.9% | 29.9% | 33.4% |
| 8.0% | 21.8% | 27.3% | 32.1% | 36.2% | 39.9% |
| 13.0% | 27.4% | 33.2% | 38.2% | 42.5% | 46.4% |
| 18.0% | 33.0% | 39.1% | 44.3% | 48.8% | 52.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newszacks.com·5h ago·Neutral
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗